A few weeks ago NIH posted its 'categorical spending' document that includes figures for fiscal year '17 (which starts Oct. 1). This document showed $7m in (extramural) spending for FY17 (note this figure does not include funds spent on campus, like the upcoming inpatient study). There was some consternation about this low figure, which did not seem to reflect talk about new funds being committed by Koroshetz et al. at the teleconference last week. So I asked Marian Emr, communications director for NINDS about it. Her answer was basically what I expected. If you translate from bureaucratise into English, you'll see she's saying that the figure is subject to change. "The RCDC website has estimates for FY 2016 and FY 2017 by category as well as the actuals for prior years. The estimates are based on a combination of factors – general or specific budget guidance as well as any category-specific information provided by the ICs based on their scientific plans or other expertise. However, actuals can turn out different than the estimates for many reasons. The peer review process is a major reason, as we may get more or fewer high quality applications than the prior year. A better sign of NIH intentions might be a new Funding Opportunity Announcement, for example. Basically, then, the figures posted for future year funding for ME/CFS were based on general budget guidance and not on any of the plans that NIH program staff are now developing to augment research in this area."